(Q36273444)

13 August 2017

1 reference

title

Rasagiline in the pharmacotherapy of Parkinson's disease--a review (English)

1 reference

13 August 2017

0 references

1 reference

1 reference

1

Olivier Rascol

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

12

1 reference

13 August 2017

page(s)

2061-2075

1 reference

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Treatment interventions for Parkinson's disease: an evidence based assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Clinical applications of MAO-inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

A comparison of the distribution of neurotransmitters in brain regions of the rat and guinea-pig using a chemiluminescent method and HPLC with electrochemical detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Neuroprotective treatment for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Rasagiline: an anti-Parkinson drug with neuroprotective activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

The essentiality of Bcl-2, PKC and proteasome–ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Atypical cancer pattern in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Worldwide occurrence of Parkinson's disease: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.12.2061

10.1517/14656566.6.12.2061

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference